Skip to main content
PLOS Medicine logoLink to PLOS Medicine
. 2019 Dec 23;16(12):e1002994. doi: 10.1371/journal.pmed.1002994

The 2016 California policy to eliminate nonmedical vaccine exemptions and changes in vaccine coverage: An empirical policy analysis

Sindiso Nyathi 1,, Hannah C Karpel 2,, Kristin L Sainani 1, Yvonne Maldonado 1,3, Peter J Hotez 4,5,6,7, Eran Bendavid 8, Nathan C Lo 9,*
Editor: Lars Åke Persson10
PMCID: PMC6927583  PMID: 31869328

Abstract

Background

Vaccine hesitancy, the reluctance or refusal to receive vaccination, is a growing public health problem in the United States and globally. State policies that eliminate nonmedical (“personal belief”) exemptions to childhood vaccination requirements are controversial, and their effectiveness to improve vaccination coverage remains unclear given limited rigorous policy analysis. In 2016, a California policy (Senate Bill 277) eliminated nonmedical exemptions from school entry requirements. The objective of this study was to estimate the association between California’s 2016 policy and changes in vaccine coverage.

Methods and findings

We used a quasi-experimental state-level synthetic control analysis and a county-level difference-in-differences analysis to estimate the impact of the 2016 California policy on vaccination coverage and prevalence of exemptions to vaccine requirements (nonmedical and medical). We used publicly available state-level data from the US Centers for Disease Control and Prevention on coverage of measles, mumps, and rubella (MMR) vaccination, nonmedical exemption, and medical exemption in children entering kindergarten. We used county-level data individually requested from state departments of public health on overall vaccine coverage and exemptions. Based on data availability, we included state-level data for 45 states, including California, from 2011 to 2017 and county-level data for 17 states from 2010 to 2017. The prespecified primary study outcome was MMR vaccination in the state analysis and overall vaccine coverage in the county analysis.

In the state-level synthetic control analysis, MMR coverage in California increased by 3.3% relative to its synthetic control in the postpolicy period (top 2 of 43 states evaluated in the placebo tests, top 5%), nonmedical exemptions decreased by 2.4% (top 2 of 43 states evaluated in the placebo tests, top 5%), and medical exemptions increased by 0.4% (top 1 of 44 states evaluated in the placebo tests, top 2%). In the county-level analysis, overall vaccination coverage increased by 4.3% (95% confidence interval [CI] 2.9%–5.8%, p < 0.001), nonmedical exemptions decreased by 3.9% (95% CI 2.4%–5.4%, p < 0.001), and medical exemptions increased by 2.4% (95% CI 2.0%–2.9%, p < 0.001). Changes in vaccination coverage across counties after the policy implementation from 2015 to 2017 ranged from −6% to 26%, with larger increases in coverage in counties with lower prepolicy vaccine coverage. Results were robust to alternative model specifications. The limitations of the study were the exclusion of a subset of US states from the analysis and the use of only 2 years of postpolicy data based on data availability.

Conclusions

In this study, implementation of the California policy that eliminated nonmedical childhood vaccine exemptions was associated with an estimated increase in vaccination coverage and a reduction in nonmedical exemptions at state and county levels. The observed increase in medical exemptions was offset by the larger reduction in nonmedical exemptions. The largest increases in vaccine coverage were observed in the most “high-risk” counties, meaning those with the lowest prepolicy vaccine coverage. Our findings suggest that government policies removing nonmedical exemptions can be effective at increasing vaccination coverage.


In an empirical policy analysis, Nyathi and colleagues estimate changes in vaccine coverage associated with the 2016 California policy (Senate Bill 277) restricting non-medical exemptions for children’s school immunization requirements

Author summary

Why was this study done?

  • Vaccine hesitancy, often parental reluctance or refusal to vaccinate their children, is a growing challenge in public health; however, there is debate on the role of government-level vaccination policies to address this problem.

  • Limited empirical research has evaluated the impact of governmental vaccination policies that restrict the ability of parents to obtain nonmedical exemptions from routine vaccination requirements.

  • The 2016 California vaccine policy (Senate Bill 277) that eliminated nonmedical childhood vaccination exemptions provides an opportunity to empirically estimate the impact of a governmental state-level policy on vaccine coverage.

What did the researchers do and find?

  • We evaluated the 2016 California vaccine policy by applying a synthetic control analysis with state-level data and a difference-in-differences analysis with county-level data to estimate the relationship between the policy and changes in measles, mumps, and rubella (MMR) or overall vaccine coverage, nonmedical exemptions, and medical exemptions.

  • At the state level, the California vaccine policy was associated with a 3.3% increase in MMR vaccination coverage, a 2.4% decrease in nonmedical exemptions, and a 0.4% increase in medical exemptions.

  • At the county level, the California vaccine policy was associated with a 4.3% increase in overall vaccination, a 3.9% decrease in nonmedical exemptions, and a 2.4% increase in medical exemptions. The largest increases in postpolicy county-level coverage occurred in counties with lower prepolicy vaccine coverage.

What do these findings mean?

  • Our study found that the 2016 California policy to eliminate nonmedical childhood vaccination exemptions was associated with an increase in vaccination coverage and a decrease in nonmedical exemptions.

  • The study findings support the hypothesis that government policies can be an effective tool to increase vaccination coverage, especially in the most “high-risk” (low vaccine coverage) settings.

Introduction

Vaccine hesitancy, defined as the reluctance or refusal to vaccinate despite the availability of vaccinations, is a growing public health challenge in the US and globally [13]. The decline in vaccination rates, driven by vaccine hesitancy and lack of confidence in vaccines, has led to recent outbreaks of vaccine-preventable diseases and threatens the public health gains made against these infectious diseases over past decades [46]. The factors driving vaccine hesitancy are complex and include misconceptions and misinformation about vaccine safety, low perceived risk of infectious diseases, and lack of trust in healthcare providers [7, 8].

The policy debate surrounding vaccine hesitancy in the US has focused on vaccine exemptions, which provide an option for parents to waive current vaccination requirements for entry into school or daycare [911]. Currently, 18 states allow nonmedical exemptions to school vaccine requirements based on philosophical, personal, or other beliefs [4, 12]. Notably, all states permit medical exemptions to school immunization requirements for clinical conditions in which vaccination would be contraindicated (e.g., immunosuppression and receipt of live attenuated vaccines). Recent work indicates that in states allowing these nonmedical exemptions, the numbers of nonmedical exemptions are as high as 15%–25% in some counties. In 2019, measles emerged in seven of the 14 urban counties previously identified as high risk due to nonmedical exemptions [7]. However, there continues to be debate surrounding the effectiveness of policies that restrict nonmedical exemptions, with ongoing legislative discourse across the US [12].

Following a series of high-profile exposures and outbreaks of vaccine-preventable diseases—including a measles outbreak in Orange County, CA—California passed Senate Bill 277 (SB277), which eliminated a previous policy that allowed nonmedical exemptions to school immunization requirements [1317]. Although previous observational studies have suggested that coverage increased in California after the policy’s implementation, the policy’s effectiveness remains unclear given natural variation in vaccination rates and lack of controlled policy evaluation [1821]. Furthermore, the rate of medical exemptions in California increased after the policy, causing concerns that children who had received nonmedical exemptions were instead receiving medical exemptions, thus limiting the policy’s ability to increase overall vaccine coverage [7, 22].

The aim of our study was to conduct a rigorous, controlled analysis to estimate the effectiveness of California’s policy restricting nonmedical exemptions to increase vaccination coverage. To address ongoing debate surrounding these governmental policies, we provide a quasi-experimental, controlled analysis to evaluate the association between California’s policy and vaccination and exemption outcomes.

Methods

Data sources and study outcomes

We performed two empirical analyses to estimate the association of the 2016 California policy with changes in vaccination coverage and exemptions: (1) a synthetic control analysis, in which we used state-level data to create a hypothetical counterfactual “synthetic control California” to compare with the real California; and (2) a difference-in-differences analysis, in which we compared county-level data from California and control states. The California policy (SB277) went into effect on July 1, 2016, corresponding with the 2016–2017 school year. Our study objectives, methods, and planned analyses were prespecified in a preanalysis plan (S3 Appendix) [23].

For the state-level synthetic control analysis, we used publicly available state-level data from the US Centers for Disease Control and Prevention (CDC) SchoolVaxView website [24]. These data are collected by state immunization programs and aggregated by the CDC [25, 26]. Data were available from 2009 to 2017 (S1 Appendix). Data for the 2010–2011 school year were unavailable because they were not verified, so only data from 2011 onward were used in this analysis. The primary outcome for the state-level analysis was prespecified as measles, mumps, and rubella (MMR) vaccine coverage, defined as the proportion of children entering kindergarten who have received the two-dose MMR vaccine by the start of the school year. The secondary outcomes were the proportion of children entering kindergarten at the start of the school year with medical exemptions or the proportion entering kindergarten with nonmedical exemptions. We included medical and nonmedical exemptions as outcomes to evaluate whether any compensatory increases in medical exemptions were observed to be associated with the policy. We used a range of publicly available state covariate data (S1 Table). We obtained demographic data (e.g., education, income) from the US Census Bureau [27]. Data on health-related characteristics were retrieved from the Data Resource Center for Child and Adolescent Health and the Centers for Medicare and Medicaid Services [28, 29]. All results are presented as absolute percentage changes in MMR coverage and medical and nonmedical exemptions.

For the county-level difference-in-differences analysis, we used county-level data individually requested from state departments of public health. These data are compiled by county health departments using data submitted by public and private schools and then submitted to state departments of public health. We contacted health departments in all 50 states and the District of Columbia to request data. We received full county-level data from California and 16 other states for overall vaccination coverage and 17 states for vaccination exemptions (S4 Fig). When counties did not report overall vaccine coverage, we used county-level MMR coverage as a proxy for overall coverage. Missing county-level outcomes data were either imputed or excluded from the analysis, depending on the proportion of missing data (S2 Appendix). The primary outcome for the county-level analysis was prespecified as overall vaccination coverage, defined as the proportion of children entering kindergarten with all required vaccines at the start of the school year. The immunizations required to enroll in kindergarten vary by state but generally include MMR, polio, chicken pox (varicella), and diphtheria, tetanus, and pertussis (DTaP) [30]. The secondary outcomes were the proportion of children entering kindergarten at the start of the school year with medical exemptions or the proportion entering kindergarten with nonmedical exemptions. We used covariate data from the American Community Survey (ACS) [31]. In our final dataset, we only included counties with a population of at least 65,000 based on availability of covariate data. Additional information on covariate selection is described in S2 Appendix. All results are presented as absolute percentage changes in overall vaccination coverage and medical and nonmedical exemptions.

The primary outcome was MMR vaccine coverage in the state-level analysis and overall vaccine coverage in the county-level analysis. This difference in primary outcomes between analyses was prespecified and based on data availability because states do not report overall vaccine coverage to the CDC. We assumed state-level MMR coverage was a good proxy for overall coverage and stated this in our preanalysis plan (S3 Appendix). Furthermore, because the definitions of medical and nonmedical exemptions include children with exemptions for any vaccine and not just the MMR vaccine, for any given state the three outcomes did not always sum to one. In both the state- and county-level analyses, we used data for children entering kindergarten. Kindergarten is the school grade for children ages 5–6 years in the US and commonly the entry level into school. This age group is most likely to be affected by the policy change given the age of the children in relation to immunization requirements. Although the 2016 California policy also requires younger-aged children in preschool or daycare to have completed all the relevant vaccinations, kindergarten is the beginning of formal education and, as such, local and state health departments routinely collect immunization data for children in kindergarten.

Statistical analysis

We used a synthetic control study design to estimate the relationship between the California policy and vaccination coverage and exemptions at the state level. The synthetic control method is a statistical tool designed for comparative case studies, such as policy evaluations, in which only a single treated unit is available (e.g., state-level policy) [3234]. The approach constructs a hypothetical control state (i.e., a “synthetic control California”) that matches the treated state (i.e., actual California) on the prepolicy outcome. The resulting synthetic control California provides a counterfactual estimation of the study outcome during the postpolicy period in the treated state in the absence of the treatment—i.e., it projects the outcome for California in the absence of the vaccine policy. The synthetic California is constructed with a weighted combination of control states. The synthetic control optimization algorithm estimates a weight for all nonexperimental states that minimizes the difference between the actual California and the synthetic California in the pretreatment period. Most states receive a zero weight, and only states with nonzero weights provide information for the construction of the synthetic control.

We created a synthetic control for California using untreated states as potential controls. The synthetic California was created by matching on average prepolicy outcomes (i.e., vaccine coverage and prevalence of exemptions) and demographic and health-related characteristics. These characteristic covariates were chosen using a stepwise variable selection process and cross-validation procedure to avoid overfitting (S1 Appendix). States were excluded from the construction of the synthetic control if they were missing relevant data. The key effect size for each study outcome was the difference in pre- to postpolicy change between California (i.e., the treated state) and the synthetic control California (i.e., the hypothetical untreated state). We constructed a unique synthetic control for each of the three outcomes, per convention given the data-driven nature of the process. This resulted in three synthetic control California states—one corresponding to each of the three outcomes (one primary, two secondary).

To assess whether the effect size in the synthetic control analysis was meaningful, we used conventional placebo testing. Whereas regression models provide confidence intervals (CIs) and p-values based on frequentist assumptions, inference in synthetic control methods is grounded in placebo tests (also known as permutation tests). In placebo tests, we reevaluate the effect size under the null condition (i.e., repeating the synthetic control method for each of the untreated states). The resulting placebo effect sizes for each of the control states quantify the variation in the outcome under the null hypothesis. By comparing them to the actual (California) effect size, we can determine whether the observed effect size in the treated unit is meaningful or whether it is similar in magnitude to the variation in the outcome in the absence of a treatment. The latter case would imply that our intervention or policy is not statistically meaningful [35, 36]. To conduct the placebo tests, we individually reassigned treatment status to each of the other states in the control pool. We then created a synthetic control for the new state and assessed the resulting effect size for every state in the dataset. We compared effect sizes for each state relative to California for all outcomes (S1 Appendix). We prespecified an effect size as meaningful if California was in the top fifth percentile of states.

We used a difference-in-differences study design to evaluate the association between the California policy and vaccination coverage and exemptions at the county level. The difference-in-differences design estimates the relative change in vaccination coverage and exemptions over time associated with the California policy as the difference between the treated group of counties (California) before and after the policy implementation and the control counties (counties not in California) before and after the policy implementation. To assess the parallel trends assumption required for the difference-in-differences methodology, we plotted the data for California and the control counties before the policy’s implementation (S2 Appendix). We used an ordinary least squares regression model for all outcomes and calculated robust standard errors clustered by county. We included an adjusted analysis with prespecified county-level characteristics (S2 Appendix).

Sensitivity analysis

We conducted sensitivity analyses to evaluate the robustness of our models (S1 Appendix and S2 Appendix) [37]. In the synthetic control and difference-in-differences analyses, we reran the models, iteratively excluding a single state from the control pool. These “leave-one-out” tests allowed us to evaluate the influence of individual states in the control pool on the effect size. For the county-level analysis, we performed a subanalysis in which we analyzed the data from states reporting complete overall vaccination coverage and excluding states that reported only MMR coverage. Finally, for the state-level analysis, we reran the model with varying combinations of characteristic covariates to evaluate the influence of the covariate combination on the outcome.

This study is reported per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (S4 Appendix). All statistical analyses were conducted in R (version 3.5.1). Public datasets and analytical materials are available online (S1 Table) [38, 39]. This was not human subjects research as the study relied on publicly available, secondary and aggregated data sources and was exempt from Stanford University’s Institutional Review Board approval.

Results

We included state-level vaccination and exemption data for 45 states, including California, from 2011 to 2017 (states excluded due to missing data are shown in S2 Table). The average prepolicy MMR vaccination coverage at the state level in the 2015 school year was 94.2% and ranged across states from 87.1% to 99.4% (94.5% in California). The average prepolicy nonmedical exemption prevalence in 2015 was 2.2% and ranged across states from 0.4% to 6.2% (2.4% in California); the average prepolicy medical exemption prevalence was 0.3% and ranged across states from 0.1% to 1.2% (0.2% in California).

We included county-level vaccination and exemption data for 17 states from 2010 to 2017 based on availability of data from state departments of public health (S6 Table). In California, the mean prepolicy county-level vaccination coverage in 2015 was 92.6% (95% CI 91.8–93.4) and ranged across counties from 68.9% to 100%, the prepolicy county average for nonmedical exemption prevalence was 3.1% (95% CI 2.5–3.6) and ranged across counties from 0% to 21.9%, and the prepolicy county average for medical exemption prevalence was 0.21% (95% CI 0.18–0.23) and ranged across counties from 0% to 1.7%.

State-level analysis

For each of the three state-level outcomes, the synthetic control California matched the observed California in the prepolicy period (Fig 1). The synthetic control California for each of the three outcomes was predominantly composed of three to five control states, with all other states having minimal weights (Fig 2). No single state had a weight greater than 50% except for Texas in the synthetic California for the nonmedical exemptions outcome. In this state-level analysis, we estimated that the 2016 California policy was associated with a 3.3% increase in MMR coverage, from 94.5% in 2015, relative to its synthetic control in the postpolicy period (top 2 of 43 states evaluated in the placebo tests, top 5%). The largest improvement in MMR coverage occurred in North Dakota (3.6%). The 2016 California policy was associated with a 2.4% decrease in nonmedical exemptions in the postpolicy period (top 2 of 43 states evaluated in the placebo tests, top 5%), from 2.4% in 2015, whereas medical exemptions increased by 0.4% (top 1 of 44 states evaluated in the placebo tests, top 2%), from 0.2% in 2015 (Fig 3). The largest decrease in nonmedical exemptions occurred in Vermont (2.8%). California had the largest increase in medical exemptions, followed by Maryland (0.2% increase).

Fig 1. State-level analysis of the 2016 California policy using synthetic control methodology on childhood vaccination and exemption outcomes.

Fig 1

We constructed a synthetic control state for California for three study outcomes of MMR coverage (top), nonmedical exemptions (bottom left), and medical exemptions (bottom right). The synthetic control state (red) is estimated to match the study outcomes for actual California (blue) before the policy (indicated by dotted blue line, which is before the 2016–2017 school year). The figure shows the observed difference between the outcome in the actual treated California and the synthetic control California after the policy. MMR, measles, mumps, and rubella.

Fig 2. Weights of the control states to construct the “synthetic control California” for state-level analysis of three study outcomes.

Fig 2

The synthetic control California was constructed as a hypothetical control state from a weighted sum of the untreated states (i.e. the control pool). The weights were calibrated to match the prepolicy vaccine outcome for California. This figure shows the weights of the control states for each of the three outcomes: MMR coverage (top), nonmedical exemptions (bottom left), and medical exemptions (bottom right). MMR, measles, mumps, and rubella.

Fig 3. Placebo testing for the state-level analysis of the 2016 California policy using synthetic control methodology.

Fig 3

Placebo testing is used in synthetic control analyses to determine whether an identified relationship is statistically meaningful. We prespecified a meaningful relationship for the 2016 California policy as a change in the hypothesized direction (increase in vaccination coverage, decrease in nonmedical exemption, increase in medical exemption) in the top fifth percentile of all states. Placebo testing was done by repeating the methodology for each of the control states individually to estimate the percent change in vaccine coverage or exemptions that would be measured if the policy occurred in the control state the same year as California; we then compared the estimated effect sizes. The estimated percent change by state is presented for three study outcomes of MMR coverage (top), nonmedical exemptions (bottom left), and medical exemptions (bottom right). MMR, measles, mumps, and rubella.

County-level analysis

In the county-level analysis, we found that the trends for outcome variables were relatively similar between California counties and counties in control states in the prepolicy period (S5 Fig). Overall vaccination was generally similar in the prepolicy period, although California counties had slightly lower vaccination levels and greater variation than control counties. Prepolicy variation in nonmedical exemptions for California was greater than for control states (S7 Table). In the county-level analysis, we estimated that the California policy was associated with a 4.3% (95% CI 2.9–5.8, p < 0.001) absolute increase in vaccine coverage for children entering kindergarten in California compared with those in control states (Table 1). The policy was also associated with a 3.9% (95% CI 2.4–5.4, p < 0.001) absolute decrease in nonmedical exemptions and a 2.4% (95% CI 2.0–2.9, p < 0.001) absolute increase in medical exemptions compared with counties in control states (Table 1). We also estimated coefficients for the characteristic demographic covariates included in the model. Income and education status of less than a high school degree were associated with increases in vaccination coverage and decreases in medical and nonmedical exemptions (Table 1). The percentage of uninsured children was significantly associated with a small increase in medical exemptions. Education status of some college as well as bachelor’s degree or beyond were significantly associated with small decreases in nonmedical exemptions, whereas race (defined as percent white, based on prior literature [40]) and percent of uninsured children were significantly associated with small increases in nonmedical exemptions (Table 1).

Table 1. County-level analysis of changes in vaccination coverage associated with the 2016 California policy using a difference-in-differences regression.

Parameter Overall vaccination coverage (95% CI)a p-Value Nonmedical exemptions prevalence (95% CI)b p-Value Medical exemptions prevalence (95% CI)b p-Value
2016 California policyb 4.3 (2.9–5.8) <0.001 −3.9 (5.4–2.4) <0.001 2.4 (2.0–2.9) <0.001
Median income per US$10,000 (no) 1.0 (0.9–2.0) <0.001 −0.3(0.4–0.08) 0.005 −0.3 (0.4–0.1) 0.002
Mean household size (no) −0.1 (−2.3 to 2.1) 0.9 0.2 (−0.6 to 1.0) 0.7 0.5 (−0.3 to 1.3) 0.3
Population per 100,000 (no) −0.1 (−0.9 to 0.6) 0.7 0.01 (−0.03 to 0.04) 0.7 0.03 (−0.02 to 0.08) 0.2
Poverty per 1,000 (%) −0.4 (−4.6 to 3.8) 0.8 −0.5 (−2.0 to 1.0) 0.5 0.05 (−0.9 to 1.0) 0.9
White (%) −0.03 (−0.06 to 0.01) 0.2 0.03 (0.01–0.04) 0.001 0.003 (−0.01 to 0.01) 0.6
Education: Less than high school (%) 0.5 (0.2–0.7) <0.001 −0.3 (0.4–0.2) <0.001 −0.09 (0.1–0.04) <0.001
Education: Some college or less (%) 0.2 (−0.03 to 0.4) 0.1 −0.2 (0.2–0.09) <0.001 −0.02 (−0.07 to 0.02) 0.3
Education: Bachelor's degree or higher (%) 0.07 (−0.2 to 0.3) 0.7 −0.1 (0.2–0.09) <0.001 −0.01 (−0.06 to 0.05) 0.8
Uninsured children (%) 0.08 (−0.01 to 0.2) 0.1 0.09 (0.04–0.1) <0.001 0.06 (0.04–0.08) <0.001

aRobust standard errors, clustered by county.

bDifference-in-differences estimates represent relative change in county-level vaccination and exemption prevalence for children entering kindergarten in California before and after the 2016 policy compared with children entering kindergarten before and after the policy in counties from control states.

Abbreviations: CI, confidence interval; no, number

There was variation in vaccination coverage and exemptions across counties before and after the policy implementation. Counties with a higher proportion of prepolicy nonmedical exemptions in 2015 (i.e., “hot spots” most at risk of outbreaks) had larger decreases in nonmedical exemptions following the policy’s implementation (Fig 4). Likewise, counties with lower prepolicy overall coverage had the largest increases in overall coverage following the policy’s implementation. The absolute change in vaccination coverage between 2015 and 2017 across counties in California ranged from −6% to 26%, with 12/57 (21.1%) of counties decreasing coverage, 28/57 (49.1%) experiencing an increase in coverage between 0.1 and 4 percentage points, and 17/57 (29.8%) experiencing an increase in coverage >4 percentage points (S8 Table). For nonmedical exemptions, 10/57 (17.5%) of counties in California either had no change or an increase, and 47/57 (82.5%) of counties had a decrease in nonmedical exemptions ranging from −0.1% to −21.5% between 2015 and 2017. All counties had an absolute increase in medical exemptions, ranging from 0.5% to 9.3%. Plumas County, population 18,742, experienced the 9.3% rise in medical exemptions, from 1.0% in 2015 to 10.3% in 2017 (S8 Table).

Fig 4. Postpolicy changes in county-level vaccination coverage and exemptions as a function of prepolicy prevalence.

Fig 4

This figure plots the change in overall vaccination coverage and exemptions before and after the policy for each county in California as it related to their prepolicy (2015) prevalence. In counties with greater prepolicy prevalence of nonmedical exemptions, there were larger decreases in nonmedical exemptions following the policy. Counties with lower prepolicy overall vaccination coverage had greater changes in overall coverage following the policy’s implementation. Note that the axis magnitudes are different for each plot based on baseline magnitude of outcome.

Sensitivity analysis

The study findings were overall robust to various sensitivity analyses. In both analyses, changing the control data included did not change the overall findings (S5 Table and S9 Table). In the state-level analysis, the effect size was robust to changes in the characteristic covariates used in the model (S4 Table). In the county-level analysis, the subanalysis excluding states reporting MMR coverage did not alter the effect size (S10 Table). Details on the sensitivity analysis are included in S1 Appendix and S2 Appendix.

Discussion

In this empirical policy analysis, we evaluated California’s 2016 policy removing nonmedical vaccine exemptions and found evidence that the policy was associated with an increase in vaccination coverage in children entering kindergarten. At the state level, the policy was associated with a 3.3% increase in MMR coverage and a 2.4% reduction in nonmedical exemptions. The policy was also associated with a 0.4% increase in medical exemptions. At the county level, often the counties with high baseline exemption prevalence and most “at risk” of an outbreak had the largest increases in vaccine coverage from the policy. Despite concerns around the observed increase in medical exemptions, our study found that the policy was associated with an overall increase in vaccine coverage. The use of two independent state- and county-level analyses with consistent results provides evidence to support considering the adoption of similar governmental policies eliminating nonmedical exemptions to help address the growing public health challenge of vaccine hesitancy across the United States and globally.

Previous descriptive analyses examined the impact of the California policy shortly after its implementation. These analyses found an increase in overall vaccination coverage among students from 92.8% in 2015 to 95.1% in 2017 along with a decrease in nonmedical exemptions [7, 22]. However, the policy’s effectiveness remained unclear because these analyses did not account for variation and trends in vaccine coverage across the US. There was also an increase in medical exemptions (from 0.2% in 2015–2016 to 0.7% in 2017–2018) that might have offset the described decreases in nonmedical exemptions [18, 22]. Two recent studies provided additional descriptive analyses of the impact of the California vaccine policies on vaccination coverage [20, 21]. In one study, the authors used county-level data for California to report the changes in the percentage of children entering kindergarten with up-to-date vaccination status, as well as geographic clustering of unvaccinated children associated with three California vaccination policies. In a subsequent study, the authors extended this work to focus specifically on SB277, the 2016 California vaccine policy. Both studies similarly found an increased percentage of children entering kindergarten with all vaccinations completed postimplementation of the California policy, though attribution to SB277 is limited by availability of comparison units to form a control group. This leaves open the possibility that observed changes may be over- or underestimated, depending on the secular trends. Our study further extended this work by providing a controlled, quasi-experimental methodological approach to estimate the impact of the 2016 California vaccine policy. Taken together, these studies contribute robust evidence to support the conclusion that vaccination coverage increased after the California policy’s implementation.

In this study, in both the county- and state-level analyses, nonmedical exemptions decreased and medical exemptions increased, a trend that supports our conclusion that the observed increase in vaccination coverage in California is associated with the implementation of the 2016 policy rather than confounding factors. Additionally, although the rise in medical exemptions could indicate that some children who may have received nonmedical exemptions in the past are now receiving medical exemptions, the net effect following the California policy was still an increase in vaccination coverage. Notably, new legislation was recently approved in California to require centralization of medical exemptions, similar to policies in place in Mississippi and West Virginia—states that also do not allow nonmedical exemptions for school entry. A centralized review may further increase vaccination coverage in California [12].

In our state-level synthetic control analysis, we used placebo testing to evaluate whether the estimated changes in study outcomes (e.g., vaccine coverage) associated with the California policy were statistically meaningful. The observed increase in MMR coverage in California associated with the 2016 policy was much greater than the changes in the majority of the placebo states and met our prespecified threshold for a significant finding (Fig 3, S3 Fig). However, we also observed notable changes in a select number of placebo states. North Dakota had an increase in coverage of 3.6% relative to its synthetic control during the year of the policy—0.3% larger than the increase in California attributable to the policy. We did not find evidence that North Dakota implemented any statewide vaccination policies at this time. The observed increase could be due to the state’s continuing efforts to address vaccine hesitancy through other mechanisms. Vermont had the largest decrease in nonmedical exemptions, 2.8% relative to its synthetic control during the year of the policy—0.4% larger than the decrease seen in California. This is likely due to Vermont’s 2015 policy, which removed philosophical exemptions [41]. Notably, the number of children enrolled in kindergarten in North Dakota and Vermont in 2016 was approximately 10,000 and 6,500, respectively, whereas the kindergarten enrollment for California in the same year was approximately 521,000 [31]. Therefore, despite the modestly larger percentage changes in smaller states like North Dakota and Vermont, the absolute number of children affected is much larger in California. Nonmedical exemptions in California showed a slight decrease in 2014. This may have been a result of another California policy passed in 2014 that required parents seeking exemptions to provide signed documentation from a healthcare provider [42].

Although the state-level increase in vaccination coverage was modest (approximately 3%), this estimate should be interpreted in the context of county-level variation in vaccine coverage and risk of outbreaks. Mainly, California counties with higher prevalence of prepolicy nonmedical exemptions and most at risk for outbreaks had larger improvements in overall coverage. Existing evidence suggests that the potential for infectious disease outbreaks is driven by hot spots of low vaccine coverage, meaning some counties may have particularly low coverage and be prone to outbreaks [4, 7, 12]. States with laws permitting personal belief exemptions or easily obtainable exemptions have greater hot spots, with high levels of nonmedical exemptions and outbreak risk, compared to states with stricter exemption laws [12]. When examining county-level data, we found a range of effect sizes for the change in vaccination coverage between 2015 and 2017, from a 6% decline in Sierra County to a 26% increase in Trinity County (S8 Table). The county-level variation in the absolute change in overall vaccination coverage and exemptions suggests that the effectiveness of the policy may be higher in most at-risk (i.e., low coverage) hot spots. The variation in the change in vaccination coverage across counties before and after the policy implementation may help explain why the increase in overall coverage does not equal the difference between the reduction in nonmedical exemptions and the increase in medical exemptions. This discrepancy may also be because our definitions of the outcome variables as the state- or county-reported vaccination and exemption percentages do not reflect missing certificate or voucher data from schools.

The importance of the observed increases in vaccine coverage in California after the implementation of the policy is further illustrated by considering how small changes in coverage have disproportionate effects on the number and size of outbreaks, as well as on public health costs [6]. A recent modeling study predicted that a 5% decline in MMR vaccine coverage driven by vaccine hesitancy would result in a 3-fold increase in measles cases in children per year, corresponding with a cost of US $2.1 million [4]. Additionally, the benefit of small increases in vaccine coverage is particularly evident when approaching approximated herd immunity levels of 90%–95% vaccine coverage. In 2015, 24 California counties had coverage levels below the range needed for herd immunity; in 2017, this number was 12 counties. This finding has implications for other states, as current data suggest that many states have counties and communities below the conventional threshold for herd immunity [4]. As multiple states continue to experience outbreaks of vaccine-preventable diseases, interventions like the California policy that increase vaccine coverage levels above the required thresholds will continue to be vital. A recent analysis of the California policy suggested that legislation may need to consider local differences because areas of northern California continued to demonstrate high rates of students without up-to-date vaccination status despite the state’s intervention [20]. Our county-level analysis found a relationship between income and education, and vaccine coverage, suggesting that socio-demographic factors may play an important role in vaccine coverage. Additional research into other correlates of vaccine hesitancy in particular regions may be necessary to obtain ideal coverage in areas that remain vaccine hesitant. Finally, settings that remain at low vaccine coverage despite removal of nonmedical exemptions may require additional interventions that include local community involvement and educational programs [4345].

The study results should be interpreted in the context of the limitations of the data and study design. Vaccine coverage and exemption data are reported by schools, and data collection procedures vary by state and year. We included a subset of US states in the analysis (included sample size of N = 45 for state data, N = 16–17 for county data) based on data availability, which could potentially introduce bias. To address these limitations, we used two different datasets and methodologies that both aim to control for differences between California and control states and counties in order to assess the effectiveness of the California policy [45]. We also ran a set of sensitivity analyses that showed that our findings were robust to the states included in the control pool. For both the state- and county-level analyses, the statistical design assumed that no concurrent change occurred in 2016. To address this, we conducted a brief literature review to determine whether any concurrent interventions took place during this time and did not find any potentially confounding programs [46, 47]. The synthetic control is ideally constructed without any acute changes during the preintervention period, although California passed two policies aiming to increase vaccine coverage. In 2014, California passed AB2109, which required proof of having consulted a healthcare provider before receiving an exemption. In 2015, California introduced a second initiative meant to educate administrators on the conditional admissions requirements. The 2015 conditional entrants initiative, although effective, was limited in scope compared with the statewide policy and would only affect MMR coverage or overall exemptions and not nonmedical exemptions. In addition, these policies were unlikely to meaningfully affect our estimate because the calibration process of the synthetic control minimized these perturbations [42]. We plotted prepolicy trends in vaccination coverage and exemptions to assess the parallel trends assumption in the difference-in-differences analysis. Although the trends were similar between California and control counties before the intervention, there was greater variability in California over the years, especially for nonmedical exemptions. Finally, our analyses included only 2 years of postpolicy data, so we are unable to observe the persistence of increased coverage over time.

As vaccine hesitancy becomes a larger public health challenge in the US and globally, with vaccine-preventable disease outbreaks growing, the debate concerning state policies to remove nonmedical exemptions is ongoing. Although such policies do not address the larger problem of vaccine hesitancy, including a lack of confidence in vaccination, they effectively increase vaccination coverage. Our study finds that vaccine coverage increased and nonmedical exemptions decreased in the time period following the implementation of the California policy eliminating nonmedical exemptions. Our conclusions are strengthened by the use of two independent analyses, which both found similar results. These study results support the idea that state-level governmental policies to remove nonmedical exemptions can be effective strategies to increase vaccination coverage across the US.

Supporting information

S1 Appendix. The synthetic control method and state-level data.

(DOCX)

S2 Appendix. The difference-in-differences method and county-level data.

(DOCX)

S3 Appendix. Preanalysis plan.

(DOCX)

S4 Appendix. STROBE checklist.

STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

(DOCX)

S1 Fig. Characteristic state covariate selection cutoffs.

(DOCX)

S2 Fig. Cross validation of synthetic controls using training and testing data for variable selection.

(DOCX)

S3 Fig. Placebo plot trajectories for control states (gray) and treated state (blue).

(DOCX)

S4 Fig. Flow chart of data collection for county-level outcome data from state health departments for control states.

(DOCX)

S5 Fig. Prepolicy trends in outcome variables in California and control counties.

(DOCX)

S1 Table. Data sources for state-level synthetic control analysis.

(DOCX)

S2 Table. States excluded from control pool due to missing data.

(DOCX)

S3 Table. Characteristic covariate weights used to create the synthetic California for each outcome in base case analysis.

(DOCX)

S4 Table. Characteristic covariate sensitivity analysis for state-level synthetic control analysis.

(DOCX)

S5 Table. Control state sensitivity analysis with leave-one-out tests.

(DOCX)

S6 Table. List of control states for the county-level difference-in-differences analysis for each outcome.

(DOCX)

S7 Table. Prepolicy trends for outcome variables in California and control states.

(DOCX)

S8 Table. Change in county-level outcome variables between 2015 and 2017 for California counties.

(DOCX)

S9 Table. County-level sensitivity analysis with leave-one-out tests.

(DOCX)

S10 Table. County-level sensitivity analysis with a subset of data reporting overall vaccine coverage.

(DOCX)

Acknowledgments

We would like to thank state departments of public health for providing us with county-level vaccine coverage and exemption data and for their ongoing inspirational work to improve vaccination coverage and public health.

Abbreviations

ACS

American Community Survey

CDC

Centers for Disease Control and Prevention

CI

confidence interval

DTaP

diphtheria, tetanus, and pertussis

MMR

measles, mumps, and rubella

SB277

Senate Bill 277

STROBE

Strengthening the Reporting of Observational Studies in Epidemiology

Data Availability

The data and code files underlying the results of the study are available from the Github code repository (https://github.com/SindisoNyathi/California-Vaccine-Policy) and Figshare data repository (DOI: https://doi.org/10.6084/m9.figshare.9775496.v1).

Funding Statement

The authors received no specific funding for this work. NCL was previously supported by the Medical Scientist Training Program (Stanford University School of Medicine).

References

  • 1.Jacobson RM, St Sauver JL, Finney Rutten LJ. Vaccine hesitancy. Mayo Clinic Proceedings. 2015;90:1562–8. 10.1016/j.mayocp.2015.09.006 [DOI] [PubMed] [Google Scholar]
  • 2.Edwards KM, Hackell JM. Countering Vaccine Hesitancy. Pediatrics. 2016;138(3):e20162146 10.1542/peds.2016-2146 [DOI] [PubMed] [Google Scholar]
  • 3.Siddiqui M, Salmon DA, Omer SB. Epidemiology of vaccine hesitancy in the United States. Human Vaccines & Immunotherapeutics. 2013;9(12):2643–8. Epub 2013/11/18. 10.4161/hv.27243 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lo NC, Hotez PJ. Public Health and Economic Consequences of Vaccine Hesitancy for Measles in the United States. JAMA Pediatrics. 2017;171(9):887–92. 10.1001/jamapediatrics.2017.1695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bankamp B, Hickman C, Icenogle JP, Rota PA. Successes and challenges for preventing measles, mumps and rubella by vaccination. Current Opinion in Virology. 2019;34:110–6. 10.1016/j.coviro.2019.01.002 [DOI] [PubMed] [Google Scholar]
  • 6.Sundaram ME, Guterman LB, Omer SB. The True Cost of Measles Outbreaks During the Postelimination Era. JAMA. 2019;321(12):1155–6. 10.1001/jama.2019.1506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Olive JK, Hotez PJ, Damania A, Nolan MS. The state of the antivaccine movement in the United States: A focused examination of nonmedical exemptions in states and counties. PLoS Med. 2018;15(6):e1002578 10.1371/journal.pmed.1002578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee C, Whetten K, Omer S, Pan W, Salmon D. Hurdles to herd immunity: Distrust of government and vaccine refusal in the US, 2002–2003. Vaccine. 2016;34:3972–8. 10.1016/j.vaccine.2016.06.048 . [DOI] [PubMed] [Google Scholar]
  • 9.Opel DJ, Schwartz JL, Omer SB, Silverman R, Duchin J, Kodish E, et al. Achieving an Optimal Childhood Vaccine Policy. JAMA Pediatrics. 2017;171(9):893–6. 10.1001/jamapediatrics.2017.1868 [DOI] [PubMed] [Google Scholar]
  • 10.Omer SB, Peterson D, Curran EA, Hinman A, Orenstein WA. Legislative Challenges to School Immunization Mandates. JAMA. 2014;311(6):620–1. 10.1001/jama.2013.282869 [DOI] [PubMed] [Google Scholar]
  • 11.Opel DJ, Kronman MP, Diekema DS, Marcuse EK, Duchin JS, Kodish E. Childhood Vaccine Exemption Policy: The Case for a Less Restrictive Alternative. Pediatrics. 2016;137(4):e20154230 10.1542/peds.2015-4230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bednarczyk RA, King AR, Lahijani A, Omer SB. Current landscape of nonmedical vaccination exemptions in the United States: impact of policy changes. Expert Review of Vaccines. 2019;18(2):175–90. 10.1080/14760584.2019.1562344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.California Legislative Information. SB-277 Public health: vaccinations. (2015–2016) California Legislative Information; 2019 [cited 2019 Sep 20]. Available from: https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201520160SB277.
  • 14.Mello MM, Studdert DM, Parmet WE. Shifting Vaccination Politics—The End of Personal-Belief Exemptions in California. New England Journal of Medicine. 2015;373:785–7. 10.1056/NEJMp1508701 [DOI] [PubMed] [Google Scholar]
  • 15.Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles Outbreak—California, December 2014—February 2015. Morbidity and Mortality Weekly Report. 2015;64(6):153–4. [PMC free article] [PubMed] [Google Scholar]
  • 16.Yang YT, Barraza L, Weidenaar K. Measles Outbreak as a Catalyst for Stricter Vaccine Exemption Legislation. JAMA. 2015;314(12):1229–30. 10.1001/jama.2015.9579 [DOI] [PubMed] [Google Scholar]
  • 17.Clemmons NS, Gastañaduy PA, Fiebelkorn AP, Redd SB, Wallace G. Measles—United States, January 4—April 2, 2015. Morbidity and Mortality Weekly Report. 2015;64(14):373–6. [PMC free article] [PubMed] [Google Scholar]
  • 18.Delamater PL, Leslie TF, Yang YT. Change in Medical Exemptions From Immunization in California After Elimination of Personal Belief Exemptions. JAMA. 2017;318(9):863–4. 10.1001/jama.2017.9242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.California Department of Public Health Immunization Branch. 2017–2018 Kindergarten Immunization Assessment—Executive Summary. California Department of Public Health Immunization Branch; 2017 [cited 2019 Mar 31]. Available from: https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/Immunization/2017-2018KindergartenSummaryReport.pdf.
  • 20.Pingali SC, Delamater PL, Buttenheim AM, Salmon DA, Klein NP, Omer SB. Associations of Statewide Legislative and Administrative Interventions With Vaccination Status Among Kindergartners in California. JAMA. 2019;322(1):49–56. 10.1001/jama.2019.7924 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Delamater PL, Pingali SC, Buttenheim AM, Salmon DA, Klein NP, Omer SB. Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status. Pediatrics. 2019;143(6):e20183301 10.1542/peds.2018-3301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mohanty S, Buttenheim AM, Joyce CM, Howa AC, Salmon D, Omer SB. Experiences With Medical Exemptions After a Change in Vaccine Exemption Policy in California. Pediatrics. 2018;142(5):e20181051 10.1542/peds.2018-1051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Nyathi S, Lo NC. Effectiveness of the 2016 California Policy to Eliminate Non-Medical Exemptions on Vaccine Coverage: A Synthetic Analysis. California Vaccine Policy pre-analysis plan [cited 2019 March 12]. Available from: https://github.com/NathanLo3/Publication-codes/raw/master/California%20Vaccine%20Coverage%20Analysis-%20synth%20control%20pre-analysis%20plan.pdf. [DOI] [PMC free article] [PubMed]
  • 24.United States Centres for Disease Control and Prevention. VaxView. Atlanta, GA: United States Centres for Disease Control and Prevention; 2017 [cited 2019 Mar 1]. Available from: https://www.cdc.gov/vaccines/vaxview/index.html.
  • 25.Mellerson JL, Maxwell CB, Knighton CL, Kriss JL, Seither R, Black CL. Vaccination Coverage for Selected Vaccines and Exemption Rates Among Children in Kindergarten-United States, 2017–18 School Year. MMWR Morbidity and Mortality Weekly Report. 2018;67:1115–22. 10.15585/mmwr.mm6740a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Seither R, Calhoun K, Street EJ, Mellerson J, Knighton CL, Tippins A, et al. Vaccination Coverage for Selected Vaccines, Exemption Rates, and Provisional Enrollment Among Children in Kindergarten—United States, 2016–17 School Year. MMWR Morbidity and Mortality Weekly Report. 2017;66(40):1073–80. 10.15585/mmwr.mm6640a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.United States Census Bureau. American FactFinder. Suitland, MD: United States Census Bureau [cited 2019 Mar 01]. Available from: https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml.
  • 28.Data Resource Center for Child and Adolescent Health supported by the U.S. Department of Health and Human Services. Child and Adolescent Health Measurement Initiative. National Survey of Children’s Health 2016–2017. Data Resource Center for Child and Adolescent Health supported by the U.S. Department of Health and Human Services; 2019 [cited 2019 January 31]. Available from: https://www.childhealthdata.org/browse/survey/allstates?q=2197.
  • 29.Centers for Medicare & Medicaid Services. Office of the Actuary. National Health Statistics Group. National Health Expenditure Data: Health Expenditures by State of Residence. Baltimore, MD: Centers for Medicare & Medicaid Services. Office of the Actuary. National Health Statistics Group; 2017 [cited 2019 Jan 31]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsStateHealthAccountsResidence.html.
  • 30.Immunization Action Coalition. State Information. State mandates on immunization and vaccine-preventable diseases. Immunization Action Coalition; 2019 [cited 2019 Mar 17]. Available from: https://www.immunize.org/laws/.
  • 31.United States Census Bureau. American Community Survey (ACS). Suitland, MD: United States Census Bureau; 2019 [cited 2019 Mar 31]. Available from: https://www.census.gov/programs-surveys/acs.
  • 32.Abadie A, Gardeazabal J. The Economic Costs of Conflict: A Case Study of the Basque Country. American Economic Review. 2007;93(1):113–32. 10.1257/000282803321455188 [DOI] [Google Scholar]
  • 33.Abadie A, Diamond A, Hainmueller J. Synthetic Control Methods for Comparative Case Studies: Estimating the Effect of California’s Tobacco Control Program. Journal of the American Statistical Association. 2010;105:493–505. 10.1198/jasa.2009.ap08746 . [DOI] [Google Scholar]
  • 34.Abadie A, Diamond A, Hainmueller J. Comparative Politics and the Synthetic Control Method. American Journal of Political Science. 2012:1–16. 10.1111/j.1540-5907.2011.00545.x [DOI] [PubMed] [Google Scholar]
  • 35.Rehkopf DH, Basu S. A new tool for Case Studies in Epidemiology—the Synthetic Control Method. Epidemiology. 2018;29:503–5. 10.1097/EDE.0000000000000837 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hahn J, Shi R. Synthetic Control and Inference. Econometrics. 2017;5:52 10.3390/econometrics5040052 [DOI] [Google Scholar]
  • 37.McClelland R, Gault S. The Synthetic Control Method as a Tool to Understand State Policy. Washington, DC: The Urban Institute; 2017. [Google Scholar]
  • 38.Lo NC, Nyathi S, Karpel H. California Vaccine Policy Code Repository. [cited 2019 Jun 1]. Available from: https://github.com/SindisoNyathi/California-Vaccine-Policy.
  • 39.California Vaccine Policy Data [Internet]. Figshare. 2019. Available from: https://figshare.com/articles/California_Vaccine_Policy_Data/9775496.
  • 40.Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination Coverage Among Children Aged 19–35 Months—United States, 2016. Morbidity and Mortality Weekly Report. 2017;66(43):1171–7. 10.15585/mmwr.mm6643a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Vermont General Assembly. H.98 (Act 37): An act relating to reportable disease registries and data. Vermont General Assembly; 2015 [cited 2019 Mar 31]. Available from: https://legislature.vermont.gov/bill/status/2016/H.98.
  • 42.Buttenheim AM, Jones M, McKown C, Salmon D, Omer SB. Conditional admission, religious exemption type, and nonmedical vaccine exemptions in California before and after a state policy change. Vaccine. 2018;36(26):3789–93. 10.1016/j.vaccine.2018.05.050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ, Eskola J, et al. Strategies for addressing vaccine hesitancy-A systematic review. Vaccine. 2015;33:4180–90. 10.1016/j.vaccine.2015.04.040 [DOI] [PubMed] [Google Scholar]
  • 44.Frew PM, Lutz CS. Interventions to increase pediatric vaccine uptake: An overview of recent findings. Human Vaccines & Immunotherapeutics ISSN:. 2017;13(11):2503–11. 10.1080/21645515.2017.1367069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.O’Neill S, Kreif N, Grieve R, Sutton M, Sekhon JS. Estimating causal effects: considering three alternatives to difference-in-differences estimation. Health Services and Outcomes Research Methodology. 2016;16:1–21. 10.1007/s10742-016-0146-8 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Omer SB, Porter RM, Allen K, Salmon DA, Bednarczyk RA. Trends in kindergarten rates of vaccine exemption and state-level policy, 2011–2016. Open Forum Infectious Diseases. 2018;5 10.1093/ofid/ofx244 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Shaw J, Mader EM, Vernyi-Kellogg OK, Morley CP, Bennett BE, Yang YT. Immunization Mandates, Vaccination Coverage, and Exemption Rates in the United States. Open Forum Infectious Diseases. 2018;5(6). 10.1093/ofid/ofy130 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Caitlin Moyer

29 Aug 2019

Dear Dr. Nyathi,

Thank you very much for submitting your manuscript "Effectiveness of the 2016 California Policy to Eliminate Non-Medical Exemptions on Vaccine Coverage" (PMEDICINE-D-19-02566) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to four independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

[LINK]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org.

We expect to receive your revised manuscript by Sep 19 2019 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests.

Please use the following link to submit the revised manuscript:

https://www.editorialmanager.com/pmedicine/

Your article can be found in the "Submissions Needing Revision" folder.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

-----------------------------------------------------------

Requests from the editors:

1.Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c) In either case, changes in the analysis—including those made in response to peer review comments—should be identified as such in the Methods section of the paper, with rationale.

2. Thank you for agreeing to make your data available. The provided Github link (from Reference 29) to the dataset does not seem to work. At this time, please provide the corrected link to the data repository and accession numbers required for access.

3. Please revise your title according to PLOS Medicine's style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. "Effect of" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design ("A randomized controlled trial," "A retrospective study," "A modelling study," etc.) in the subtitle (ie, after a colon).

4. Abstract: Please quantify the main results with 95% CIs and p values.

5. Abstract: Please address the study implications without overreaching what can be concluded from the data; the phrase "In this study, we observed ..." may be useful. Specifically, please avoid causal language such as “The California policy resulted in…”.

6. Abstract: Please avoid vague statements such as "these results have major implications for policy/clinical care". Mention only specific implications substantiated by the results. Specifically, the phrase “meaningful increase” in the Conclusion section is vague.

7. At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary

8. Results: Please provide the CIs and p values for the comparison of actual vs synthetic CA analysis and county-level analysis results for post-policy changes in vaccine coverage and medical/nonmedical exemptions. Please also provide p-values for Table 1.

9. Figure S1: Please define the abbreviation “RMSPE“. Also, please show the axis beginning at zero. If this is not possible, please show a break in the axis.

10. Figure S2: Please show the axis beginning at zero. If this is not possible, please show a break in the axis.

11. Table S7: Please specify if these values are percentages.

12. Tables S9 and S10: Please provide any p-values associated with 95% CIs.

13. Please ensure that the study is reported according to the relevant guidelines, which can be found here: http://www.equator-network.org/

Please include the completed STROBE, RECORD, etc. checklist as Supporting Information. When completing the checklist, please use section and paragraph numbers, rather than page numbers. Please add the following statement, or similar, to the Methods: "This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist)."

Comments from the reviewers:

Reviewer #1: See attachment

Michael Dewey

Reviewer #2: This is a well-conducted and well-reported study on the effect of the 2016 California law removing non-medical exemptions in that state.

There are a few issues that need to be addressed to improve this manuscript.

1. In the abstract and in the introduction, you refer to vaccine hesitancy as the delay or refusal of vaccination, but hesitancy can also mean underlying lack of confidence in vaccination, even if vaccines are received. This may be a bit pedantic, but hesitance does not always equate to refusal or delay.

2. Throughout the manuscript, it should be more clear whether the % changes that are presented are relative or absolute changes. It appears they are absolute changes, but as written, it is a bit confusing.

3. A little more methodologic explanation of the synthetic control analysis would be helpful, especially for policy makers who may read this who do not have more advanced statistical training.

4. There are some reported results where % change is given without the context of baseline rates. While this is presented well in Figure 4 for the county-level analysis, it would be helpful to ensure this has the best context throughout.

5. In the discussion, third paragraph, it would be helpful to mention that ND and VT are relatively small states, compared to CA, and relatively small changes in absolute numbers of children vaccinated or exempted could make a larger impact than in CA. Additionally, some context as to the overall absolute change, in N, of the children with vaccination or without exemption, would be helpful.

Reviewer #4: This analysis evaluates the effectiveness of SB277 in California. There have been two recent publications tackling the exact same question (below). This paper does use different set of methods than those.

Pingali SC, Delamater PL, Buttenheim AM, Salmon DA, Klein NP, Omer SB. Associations of Statewide Legislative and Administrative Interventions With Vaccination Status Among Kindergartners in California. JAMA. 2019;322:49-56.

Delamater PL, Pingali SC, Buttenheim AM, Salmon DA, Klein NP, Omer SB. Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status. Pediatrics. 2019;:e20183301.

Specific concerns/issues/comments

The synthetic control approach is very interesting, but I do have some reservations about its validity in this particular scenario. There are numerous factors that can and do influence state-level UTD rates, but specifically policy changes are shocks that may interrupt and/or change prior temporal trends. In California, prior to SB277, the state enacted AB2109 two years prior to SB277, which interrupted temporal trends in the year prior (note the small decreases in NMEs in 2014 and 2015 in Fig 1. It seems that constructing a synthetic control without accounting for the different policy regimes in the potential control data over the time period (i.e., other states) may lead to an inaccurate estimate of what we should have expected in CA.

The analysis does not consider the other avenues for not up to date students to enter school in CA (conditional, not subject to immunization requirements). And, unfortunately in this case, UTD rates is not an appropriate metric to evaluate the effectiveness of SB277 because efforts other than SB277 influenced UTD rate. Specifically, the analysis does not consider the statewide effort (that occurred one year prior to SB277) to reduce Conditional entrants, which resulted in a dramatic reduction of conditional entrants statewide and a corresponding increase in UTD rate (this can be seen in Fig 1 from 2014 to 2015). The Delamater et al. paper goes into great detail on this matter.

The explanatory portion of the analysis seems somewhat underdeveloped, as the results in Table 1 are not really given much attention.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Attachment

Submitted filename: nyathi.pdf

Decision Letter 1

Caitlin Moyer

28 Oct 2019

Dear Dr. Nyathi,

Thank you very much for re-submitting your manuscript "Impact of the 2016 California Policy to Eliminate Non-Medical Exemptions on Vaccine Coverage: An Empirical Policy Analysis" (PMEDICINE-D-19-02566R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by 2 reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

[LINK]

Our publications team (plosmedicine@plos.org) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU'VE RECEIVED THE PRODUCTION REQUIREMENTS.

***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (plosmedicine@plos.org) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on plosmedicine@plos.org.

We look forward to receiving the revised manuscript by Nov 04 2019 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

------------------------------------------------------------

Requests from Editors:

1. Title: Thank you for revising your title to be consistent with PLOS Medicine’s style. To remove any confusion regarding potential causal association, please revise to “Estimated association of the 2016 California Policy to Eliminate Non-Medical Exemptions on Vaccine Coverage: An Empirical Policy Analysis” or similar.

2. Abstract: Methods and Findings: Please briefly mention the years for which data were included for the state level and county-level analyses, e.g. from your results: “We included state level vaccination and exemption data for 45 states, including California, from 2011 to 2017…” and “We included county level vaccination and exemption data for 17 states from 2010 to 2017 based on availability of data from state health departments…”.

3. Abstract: Methods and Findings: Please clarify briefly in the text what is meant by the presentation of results such as “(top 2 of 43 states, top 5%)”- does this indicate that post-policy implementation that the synthetic California ranks 2 out of 43 states included in the analysis?

4. Abstract: Conclusions: Please revise the conclusions to avoid causal and imprecise language, For the first sentence, we suggest: “The California policy was associated with an estimated increase in vaccination coverage and reduction in non-medical exemptions at state and county levels.” or similar.

5. Abstract: Conclusions: Please revise the final sentence to “Our findings suggest that government policies removing non-medical exemptions may be effective at increasing vaccination coverage.” or “The results of this study suggest that government policies removing non-medical exemptions may be effective at increasing vaccination coverage.” or similar.

6. Author summary: “Why was the study done?”: Please revise the first point to “...a growing challenge in public health; however, there is debate surrounding the role of state level vaccination policies…” or similar, to avoid unclear language. Specifically, please remove the term “substantial” from the first bullet point, as the meaning is imprecise.

7. Author summary: “What did the researchers do and find?”: Please combine the first two points, e.g. “We evaluated the 2016 California vaccine policy that eliminated non-medical childhood vaccination exemptions by applying a synthetic control analysis using state level data and a difference-in-differences analysis using county level data to estimate the relationship between the California vaccine policy and changes in MMR or overall vaccine coverage, non-medical exemptions, and medical exemptions.” or similar.

8. Author summary: “What do these findings mean?”: Please revise this point to: “Our study found that the 2016 California policy to eliminate non-medical childhood vaccination exemptions was associated with increased vaccination coverage and decreased non-medical exemptions, supporting the idea that state policies can serve as effective tools to increase vaccination coverage.” or similar.

9. Introduction: Line 142: Please remove the term “significant” from the following sentence: “However, there remains significant debate around the effectiveness of policies…” as the meaning of the term is unclear.

10. Introduction: Line 144-146: Please revise to either avoid mentioning Disneyland, (e.g. edit to “Following a large measles outbreak in 2014-15, California passed…” or similar) or provide primary reference to support that the outbreak originated/was associated with Disneyland.

11. Methods: Line 286: Please reference the specific institution that waived human subjects research approval.

12. Results: Line 375-376: Please edit sentence to “The percentage of uninsured children…” or similar.

13. Results: Line 377: Please edit “bachelor’s” to “bachelor’s degree”.

14. Results: Line 378, and where relevant throughout Methods and Results and Supporting Information: How was race/ethnicity defined and by whom? Why was race/ethnicity considered important in this study and what it is believed to represent?

15. Results: Line 381: Please remove the word “substantial” or replace with a more specific or quantitative term.

16.Results: Line 386-387: The wording here is unclear, please revise to “Although our model found an absolute 2.4% increase in medical exemptions across all counties…” or similar.

17. Results: Lines 419-423: For the sensitivity analyses, please refer to the specific supplemental figures and tables for the discussion of the results here.

18. Discussion: Lines 426-437: Please remove imprecise terms such as “robust” or “modest” unless these terms have specific quantitative meaning (if so please define).

19. Discussion: Lines 434-437: Please revise this sentence to: “The use of two independent state and county level analyses with consistent results provides evidence to support the idea that adoption of similar state policies eliminating non-medical exemptions may help to address the growing public health challenge of vaccine hesitancy.” or similar.

20. Discussion: Line 466-467: Please revise to “...Mississippi and West Virginia—states that also do not allow non-medical exemptions for school…”

21. Discussion: Line 570-572: Please revise to: “Our study finds that vaccine coverage increased and non-medical exemptions decreased in the time period following the implementation of the California policy eliminating non-medical exemptions.” or similar.

22. Discussion: Line 573-574: Please revise the final sentence of the discussion to: “These study results support the idea that state-level governmental policies to remove non-medical exemptions may be effective strategies to increase vaccination coverage in the United States.” or similar.

23. Table 1: Please define the abbreviation “CI”.

24. Table 1, and throughout: Please report p values to two decimal places if p<0.05, and to three decimal places if p<0.01.

25. Table 1: Please edit “Bachelor’s” to “bachelor’s degree”.

26. Figures 1, 2, and 3: Please define the abbreviation “MMR” in the figure legend.

27. S3 Appendix: Pre-analysis Plan, Figure 1 and Table 1: Please define the abbreviation “RMSPE”.

28. S1 Table: Please provide the links to any online data sources, where feasible.

29. S1 Table: Please define abbreviations: HMO, MMR.

30. S1 Table: Please remove “bachelor’s” in “Proportion with bachelor’s high school diploma or higher”

31. S3, S4, Table: Please define the abbreviation “BS”

32. S2, S3, S4, S5 Tables and S1, S2, and S3 Figures: Please define the abbreviation “MMR”

33. S5 Table: Please explain the meaning of the row that is empty in the middle of the table.

34. S10 Table: Please define abbreviations: CI.

35. S10 Table: “Bachelor’s” should be “bachelor’s degree”.

Comments from Reviewers:

Reviewer #1: The authors have addressed my points and clarified things.

Are they convinced that Supplementary Figure 5 does not show that changes were already occurring in California as a result of earlier legislation? That might have implications for the parallel trends assumption.

Michael Dewey

Reviewer #2: The authors have sufficiently addressed my comments.

Any attachments provided with reviews can be seen via the following link:

[LINK]

Decision Letter 2

Caitlin Moyer

20 Nov 2019

Dear Mr. Nyathi,

On behalf of my colleagues and the academic editor, Dr. Lars Åke Persson, I am delighted to inform you that your manuscript entitled "The 2016 California Policy to Eliminate Non-Medical Vaccine Exemptions: An Empirical Policy Analysis" (PMEDICINE-D-19-02566R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer's (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to https://www.editorialmanager.com/pmedicine, log in, and click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

plosmedicine.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. The synthetic control method and state-level data.

    (DOCX)

    S2 Appendix. The difference-in-differences method and county-level data.

    (DOCX)

    S3 Appendix. Preanalysis plan.

    (DOCX)

    S4 Appendix. STROBE checklist.

    STROBE, Strengthening the Reporting of Observational Studies in Epidemiology.

    (DOCX)

    S1 Fig. Characteristic state covariate selection cutoffs.

    (DOCX)

    S2 Fig. Cross validation of synthetic controls using training and testing data for variable selection.

    (DOCX)

    S3 Fig. Placebo plot trajectories for control states (gray) and treated state (blue).

    (DOCX)

    S4 Fig. Flow chart of data collection for county-level outcome data from state health departments for control states.

    (DOCX)

    S5 Fig. Prepolicy trends in outcome variables in California and control counties.

    (DOCX)

    S1 Table. Data sources for state-level synthetic control analysis.

    (DOCX)

    S2 Table. States excluded from control pool due to missing data.

    (DOCX)

    S3 Table. Characteristic covariate weights used to create the synthetic California for each outcome in base case analysis.

    (DOCX)

    S4 Table. Characteristic covariate sensitivity analysis for state-level synthetic control analysis.

    (DOCX)

    S5 Table. Control state sensitivity analysis with leave-one-out tests.

    (DOCX)

    S6 Table. List of control states for the county-level difference-in-differences analysis for each outcome.

    (DOCX)

    S7 Table. Prepolicy trends for outcome variables in California and control states.

    (DOCX)

    S8 Table. Change in county-level outcome variables between 2015 and 2017 for California counties.

    (DOCX)

    S9 Table. County-level sensitivity analysis with leave-one-out tests.

    (DOCX)

    S10 Table. County-level sensitivity analysis with a subset of data reporting overall vaccine coverage.

    (DOCX)

    Attachment

    Submitted filename: nyathi.pdf

    Attachment

    Submitted filename: Submission 2. Response to Editor.docx

    Attachment

    Submitted filename: Editor Response_2_Nov_14.docx

    Data Availability Statement

    The data and code files underlying the results of the study are available from the Github code repository (https://github.com/SindisoNyathi/California-Vaccine-Policy) and Figshare data repository (DOI: https://doi.org/10.6084/m9.figshare.9775496.v1).


    Articles from PLoS Medicine are provided here courtesy of PLOS

    RESOURCES